NeuroSense Therapeutics Ltd.

NRSN is overvalued

NASDAQ · Healthcare

FAIR PRICE

79.5%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

$0.68

MARKET PRICE

$0.14

FAIR PRICE

$0.54

MARGIN

UNDERFAIROVER

COMMUNITY BUY ZONE

UNLOCKS AT 10

Where does the market buy NRSN?

No one has priced NRSN yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.

COMMUNITY MEDIAN

▓▓▓▓▓

BUYERS AT TODAY'S PRICE

▓▓ %

0/10 INVESTORS · 10 MORE TO UNLOCK

METRICS

P/E
P/B
P/S
PEG
DIV YIELD
ROE2720.5%
ROIC1651.3%
DEBT/EQ
MKT CAP$17M

NOW AVAILABLE

Get notified when NRSN's fair price changes

Push notifications when NRSN's valuation shifts. Available on iOS and Android.

Download on the App StoreGet it on Google Play

FPI RATING

3.3/ 10

High-quality fundamentals, but volatile earnings pattern.

Analytical data, not an investment recommendation. Updated daily.

How we calculate this ↗

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$0.11CONSERVATIVE ENTRY
$0.14FAIR PRICE
$0.68MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$0.11

Fair price × 0.80

DISTANCE

83.6%

Price to entry level

At the current price of $0.68, NRSN trades 83.6% above the conservative entry level of $0.11. This entry level represents a 20% margin of safety below the calculated fair price of $0.14 — a buffer that accounts for estimation uncertainty in the valuation model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

SYNCING FEED

P/E RATIO HISTORY

SYNCING FEED

METHODOLOGY

How we calculate NRSN's fair price

NeuroSense Therapeutics Ltd.'s fair price of $0.14 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $0.68, NRSN trades 79.5% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting NRSN's risk profile.

RELATIVE · 30%

Comparing NRSN's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for NRSN, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate NRSN's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for NRSN.

Explore on Bulios

FAQ

What is the fair price of NRSN?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for NeuroSense Therapeutics Ltd. is $0.14. At the current market price of $0.68, NRSN trades 79.5% above its calculated fair value.

Is NRSN overvalued or undervalued?+

NeuroSense Therapeutics Ltd. is currently overvalued based on our valuation model. The stock trades at $0.68, which is 79.5% above the fair price of $0.14.

What is the margin of safety for NRSN?+

With a 20% margin of safety applied to the fair price of $0.14, the conservative entry level for NRSN is $0.11. At the current market price of $0.68, the stock trades 83.6% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is NRSN's fair price updated?+

We update fair price calculations for NRSN daily after market close. The current fair price of $0.14 incorporates the latest market data and sector multiples.

What factors affect NRSN's fair price calculation?+

NRSN's fair price of $0.14 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 2720.5%.

Is NRSN a good buy right now?+

At $0.68, NRSN trades 79.5% above our fair value estimate of $0.14. The stock is currently overvalued. ROE stands at 2720.5% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.

Does NRSN pay dividends?+

NRSN does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.